ezyVet vs Moderna
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Practice Management & Client Engagement
Cloud vet practice management acquired by IDEXX; Auckland New Zealand; 5,000+ clinics in US, Australia, NZ, and UK; covers patient check-in through invoicing and end-of-day reconciliation.
About
ezyVet is a cloud-based veterinary practice management and client engagement platform that provides veterinary clinics with patient records, scheduling, invoicing, billing, client communication, and analytics in a fully browser-based system, headquartered in Auckland, New Zealand and acquired by IDEXX Laboratories — the global veterinary diagnostics leader — in 2021 to extend IDEXX's software platform capabilities alongside its diagnostic products. ezyVet serves more than 5,000 veterinary clinics globally with particular strength in the United States, Australia, New Zealand, and the United Kingdom.\n\nezyVet's platform provides a comprehensive clinical workflow covering patient check-in, consultation and treatment planning, prescription management, invoicing, and end-of-day reconciliation. The two-way client communication features include automated appointment reminders via SMS and email, post-visit summaries, and a client portal where pet owners can access records and request appointments. Deep integration with IDEXX's diagnostic products — including in-clinic analyzers, reference laboratory services, and imaging systems — allows results to flow directly into patient records, providing a significant competitive advantage now that IDEXX owns the platform.\n\nAs an IDEXX-owned platform, ezyVet benefits from IDEXX's global distribution network, integration with IDEXX's full diagnostics portfolio, and the ability to bundle software with diagnostic equipment and service agreements. ezyVet competes with Provet Cloud, Vetspire, Digitail, and the legacy IDEXX Cornerstone platform in the veterinary software market. IDEXX's ownership creates both an advantage (deep diagnostics integration) and a competitive consideration for clinics that use non-IDEXX diagnostic products.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
About
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.